Sie befinden sich hier
The Mannheim Institute for Innate Immunoscience (MI3) of Heidelberg University serves as a cross-sectional hub for innovative immunology research with an emphasis on innate immunity. In close connection with the four research areas of the Medical Faculty Mannheim and the University Medical Center Mannheim, the MI3 explores the functions of innate immune cells and their tissue specific cross-talk with the adaptive immune system, non-immune and malignant cells and pathogens.
MI3-Kick-Off-Symposium and Retreat
On September 29, the MI3 - Mannheim Institute of Innate Immunoscience - invited to a top-class kick-off symposium in the "Alte Brauerei" in Mannheim. On the following day, the MI3 scientists met again for a retreat to discuss their research.
At the start of the kick-off event, Professor Dr. Adelheid Cerwenka, the Managing Director of MI3, introduced the institute, which was founded three years ago in the cross-sectional area of inflammation medicine, immunology and immunotherapies at the Mannheim Medical Faculty of Heidelberg University. MI3 stands for innovative immunological research with a focus on innate immunity. In close connection with the four research foci of the Medical Faculty and clinical foci of the University Hospital Mannheim, MI3 investigates the reactivity and function of innate immune cells in cancer, inflammation and infectious diseases.
With Professor Dr. Christian Bogdan (Friedrich Alexander University, Erlangen), Professor Dr. Alexander Dalpke (Heidelberg University Hospital), Professor Dr. Dr. Ulrike Köhl (Leipzig University Hospital and Fraunhofer Institute for Cell Therapy and Immunology, IZI, Leipzig) and Professor Dr. Nina Papavasiliou (German Cancer Research Center, DKFZ, Heidelberg), leading scientists in the field of innate immunity were recruited for an exciting program of lectures at the symposium. A particular highlight was the keynote lecture by Professor Dr. Lewis Lanier (Department of Microbiology and Immunology, University of California San Francisco; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA) entitled "Natural killer cell activation".
At the retreat the following day, scientists from MI3's core and associated departments presented their exciting MI3 research projects, followed by lively discussions. A common conclusion of both event days is that they were more than worthwhile - not only because many findings of immunological research were exchanged, which always give impulses for project ideas. There was also enough time for networking to deepen existing collaborations and to initiate new ones.
29th September 2022, 01.30 – 06:00 p.m.
30th September 2022, 09:00 a.m. – 05:00 p.m.
Medical Faculty Mannheim, Heidelberg University
Alte Brauerei, Lecture Room 2
Röntgenstrasse 7, 68167 Mannheim
We are pleased to announce that we have put together an exciting program for both our MI3-Retreat as well as for our MI3-Kick-Off Symposium featuring top international/national leaders in the field of innate immunity.
New Option of Treatment for Second-line Therapy of Advanced Oesophageal Cancer
A UMM initiated “RAMONA study” presents worldwide for the first time a combined immune therapy option with two Checkpoint inhibitors as a safe and effective treatment for older patients. Patients with advanced and refractory oesophageal squamous cell carcinoma who do not respond to the first-line radiation therapy and/or chemo therapy face poor prognosis and there has been no standard second-line therapy
The “RAMONA study” led by Professor Dr. Matthias Ebert, head of the Department of Medicine II of the University Medical Center Mannheim (UMM) and Professor of Internal Medicine at Heidelberg University was conducted in over 30 centers in Germany. This trial provides new evidence for a new treatment option with immune therapy in these older patients.
New regulator of gene expression discovered
Biochemists at MI3 and the National Cancer Institute (USA) identified the E3-ligase RNF219 as a novel inhibitor of mRNA deadenylation.
New funding to investigate the dark side of chemotherapy
DFG funds Middle East Cooperation grant to investigate the immunology behind the metastasis-promoting effects of chemotherapy.
Mannheim Institute for Innate Immunoscience
Medical Faculty Mannheim
Ludolf-Krehl-Straße 13 - 17
Phone +49 621 383-71430
Graduate Research Training Group (GRK) 2727/1
MI3 Scientific Report 2022
Adelheid Cerwenka, Prof. Dr. Director
Harald Klüter, Prof. Dr.
- Karen Bieback, Prof. Dr.
- Peter Bugert, Prof. Dr.
- Julia Kzhyshkowska, Prof. Dr.
Thomas Miethke, Prof. Dr.
Michael Neumaier, Prof. Dr.
Georg Stoecklin, Prof. Dr. Dr.
Michael Boettcher, Prof. Dr.
Steven Dooley, Prof. Dr.
Matthias Ebert, Prof. Dr.
- Elke Burgermeister, PD. Dr.
Sascha Gravius, Prof. Dr.
Jörg Heineke, Prof. Dr.
Bernhard Krämer, Prof. Dr.
- Benito Yard, Prof. Dr.
Sonja Loges, Prof. Dr. Dr.
Jan Nicolay, Prof. Dr.
Michael Platten, Prof. Dr.
Nicole Rotter, Prof. Dr.
Lucas Schirmer, Prof. Dr.
Horst Schroten, Prof. Dr.
- Christian Schwerk, Prof. Dr.
Jonathan Sleeman, Prof. Dr.
Marc Sütterlin, Prof. Dr.
- Kai Doberstein, Dr.
- Frederik Marmé, Prof. Dr.
Manfred Thiel, Prof. Dr.
- Holger Lindner, PD Dr.
- Verena Schneider-Lindner, PD Dr. Dr.
Viktor Umansky, Prof. Dr